{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:19:18Z","timestamp":1790720358978,"version":"4.1.0"},"reference-count":33,"publisher":"Society of Nuclear Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,12,5]]},"published-print":{"date-parts":[[2025,2]]},"DOI":"10.2967\/jnumed.124.268617","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T13:25:13Z","timestamp":1736342713000},"page":"238-244","source":"Crossref","is-referenced-by-count":19,"title":["<sup>177<\/sup>Lu-DOTATATE Plus Capecitabine Versus<sup>177<\/sup>Lu-DOTATATE Alone in Patients with Advanced Grade 1\/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial"],"prefix":"10.2967","volume":"66","author":[{"given":"Swayamjeet","family":"Satapathy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyush","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwani","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal R.","family":"Chandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan K.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Khosla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajender","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmandeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagwant Rai","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"2025020306150630000_66.2.238.1","first-page":"1335","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumours in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMAOncol."},{"key":"2025020306150630000_66.2.238.2","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1200\/JCO.23.01529","article-title":"Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline","volume":"41","author":"Del Rivero","year":"2023","journal-title":"J Clin Oncol."},{"key":"2025020306150630000_66.2.238.3","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13343"},{"key":"2025020306150630000_66.2.238.4","doi-asserted-by":"crossref","first-page":"e13423","DOI":"10.1111\/jne.13423","article-title":"European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca","year":"2024","journal-title":"J Neuroendocrinol."},{"key":"2025020306150630000_66.2.238.5","doi-asserted-by":"publisher","DOI":"10.1148\/rg.352140164"},{"key":"2025020306150630000_66.2.238.6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.clon.2020.10.020","article-title":"Peptide receptor radionuclide therapy: prospects for personalised treatment","volume":"33","author":"Sundl\u00f6v","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)."},{"key":"2025020306150630000_66.2.238.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2025020306150630000_66.2.238.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00572-6"},{"key":"2025020306150630000_66.2.238.9","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/MNM.0000000000001103","article-title":"177Lu-DOTATATE peptide receptor radionuclide therapy versus everolimus in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis","volume":"40","author":"Satapathy","year":"2019","journal-title":"Nucl Med Commun."},{"key":"2025020306150630000_66.2.238.10","doi-asserted-by":"crossref","first-page":"S954","DOI":"10.1016\/j.annonc.2022.07.1013","article-title":"First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177lutetium-octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: results of the OCLURANDOM trial","volume":"33","author":"Baudin","year":"2022","journal-title":"Ann Oncol."},{"key":"2025020306150630000_66.2.238.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1631-x"},{"key":"2025020306150630000_66.2.238.12","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2012.1276"},{"key":"2025020306150630000_66.2.238.13","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.1097\/RLU.0000000000001816","article-title":"Concomitant 177Lu-DOTATATE and capecitabine therapy in patients with advanced neuroendocrine tumours: a long-term-outcome, toxicity, survival, and quality-of-life study","volume":"42","author":"Ballal","year":"2017","journal-title":"Clin Nucl Med."},{"key":"2025020306150630000_66.2.238.14","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1007\/s00259-021-05236-z","article-title":"Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors","volume":"48","author":"Nicolini","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025020306150630000_66.2.238.15","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(97)80024-0"},{"key":"2025020306150630000_66.2.238.16","doi-asserted-by":"publisher","DOI":"10.1053\/srao.2001.26002"},{"key":"2025020306150630000_66.2.238.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0688-7"},{"key":"2025020306150630000_66.2.238.18","doi-asserted-by":"publisher","DOI":"10.1159\/000362558"},{"key":"2025020306150630000_66.2.238.19","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000201"},{"key":"2025020306150630000_66.2.238.20","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21493"},{"key":"2025020306150630000_66.2.238.21","doi-asserted-by":"publisher","DOI":"10.1159\/000443167"},{"key":"2025020306150630000_66.2.238.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1902-1"},{"key":"2025020306150630000_66.2.238.23","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.125336"},{"key":"2025020306150630000_66.2.238.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2743"},{"issue":"3","key":"2025020306150630000_66.2.238.25","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s00259-016-3533-z","article-title":"Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-DOTATATE","volume":"44","author":"Sansovini","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025020306150630000_66.2.238.26","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1210\/jc.2018-01991","article-title":"Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors","volume":"104","author":"Zandee","year":"2018","journal-title":"J ClinEndocrinolMetab."},{"key":"2025020306150630000_66.2.238.27","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0488"},{"key":"2025020306150630000_66.2.238.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.009"},{"key":"2025020306150630000_66.2.238.29","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1097\/RLU.0000000000003170","article-title":"Peptide receptor radionuclide therapy as first-line systemic treatment in advanced inoperable\/metastatic neuroendocrine tumors","volume":"45","author":"Satapathy","year":"2020","journal-title":"Clin Nucl Med."},{"key":"2025020306150630000_66.2.238.30","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/GO.21.00103","article-title":"177Lu-DOTATATE plus radiosensitizing capecitabine versus octreotide long-acting release as first-line systemic therapy in advanced grade 1 or 2 gastroenteropancreatic neuroendocrine tumors: a single-institution experience","volume":"7","author":"Satapathy","year":"2021","journal-title":"JCO Glob Oncol."},{"key":"2025020306150630000_66.2.238.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025020306150630000_66.2.238.32","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1200\/JCO.2022.40.16_suppl.4122","article-title":"Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET study: 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)\u2014final results","volume":"40","author":"Pavlakis","year":"2022","journal-title":"J Clin Oncol."},{"key":"2025020306150630000_66.2.238.33","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1097\/RLU.0000000000002532","article-title":"Peptide receptor radionuclide therapy combined with chemotherapy in patients with neuroendocrine tumors","volume":"44","author":"Yordanova","year":"2019","journal-title":"Clin Nucl Med."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T14:17:37Z","timestamp":1738592257000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,3]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.2967\/jnumed.124.268617"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268617","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]}}}